241 related articles for article (PubMed ID: 35262412)
1. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
2. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.
Chen H; Luthra R; Routbort MJ; Patel KP; Cabanillas ME; Broaddus RR; Williams MD
Mol Cancer Ther; 2018 Jul; 17(7):1575-1584. PubMed ID: 29695638
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in
Pappa T; Ahmadi S; Marqusee E; Johnson HL; Nehs MA; Cho NL; Barletta JA; Lorch JH; Doherty GM; Lindeman NI; Alexander EK; Landa I
Clin Cancer Res; 2021 Aug; 27(15):4256-4264. PubMed ID: 34088725
[TBL] [Abstract][Full Text] [Related]
5. Mouse Models as a Tool for Understanding Progression in Braf
Landa I; Knauf JA
Endocrinol Metab (Seoul); 2019 Mar; 34(1):11-22. PubMed ID: 30784243
[TBL] [Abstract][Full Text] [Related]
6. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
7. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
8. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT; Lee CH
J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
12. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
13. Detection of BRAF V600E Mutations With Next-Generation Sequencing in Infarcted Thyroid Carcinomas After Fine-Needle Aspiration.
Kouba E; Ford A; Brown CG; Yeh C; Siegal GP; Manne U; Eltoum IE
Am J Clin Pathol; 2018 Jul; 150(2):177-185. PubMed ID: 29868707
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
[No Abstract] [Full Text] [Related]
15. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
16. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
[TBL] [Abstract][Full Text] [Related]
17. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Next-Generation Sequencing-Based Panel to
Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
[TBL] [Abstract][Full Text] [Related]
19. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma.
Zhu ML; Zhou L; Sadri N
Virchows Arch; 2018 Sep; 473(3):371-377. PubMed ID: 29926184
[TBL] [Abstract][Full Text] [Related]
20.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
[Next] [New Search]
